Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis
Objective This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them. Methods Proteomics analysis was performed in urine samples from 10 women (mean ± SD age 76.0 ± 5.0 years) undergoing knee rep...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 64; no. 7; pp. 2260 - 2267 |
---|---|
Main Authors | , , , , , |
Format | Journal Article Web Resource |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.07.2012
Wiley Wiley Subscription Services, Inc John Wiley & Sons |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them.
Methods
Proteomics analysis was performed in urine samples from 10 women (mean ± SD age 76.0 ± 5.0 years) undergoing knee replacement surgery due to severe OA and 5 healthy women (mean ± SD age 25.6 ± 2.6 years). Protein content was analyzed by 2‐dimensional differential gel electrophoresis. Protein spots that exhibited an OA:control abundance ratio of ≥1.5 were identified by mass spectrometry. Specific enzyme‐linked immunosorbent assays were developed and validated in serum obtained from 236 healthy subjects ages 20–64 years and from 76 patients with severe radiologic knee OA (mean ± SD age 68.8 ± 11.9 years). Immunohistochemical analysis was performed on articular cartilage from tibial plateaus.
Results
Thirteen proteins within spots that were significantly modified between groups were identified. Two peptides of fibulin 3, named Fib3‐1 and Fib3‐2, were of particular interest. Two antisera directed against these peptides were used to develop immunoassays. Compared with age‐matched healthy subjects, median levels of serum Fib3‐1 and Fib3‐2 were elevated in OA patients (54.6 pM versus 85.1 pM [P < 0.0001] and 144.4 pM versus 191.4 pM [P < 0.0001], respectively). Using area under the receiver operating characteristic curve analysis, we demonstrated that Fib3‐1 and Fib3‐2 levels discriminate between OA and normal populations. Immunostaining revealed the presence of Fib3‐1 and Fib3‐2 in chondrocytes and in the extracellular matrix of the superficial layer of the fibrillated cartilage.
Conclusion
Our findings indicate that Fib3‐1 and Fib3‐2 are potential biochemical markers for the diagnosis of OA. |
---|---|
Bibliography: | ark:/67375/WNG-Q34K2WB9-N ArticleID:ART34392 istex:D12A14E6E8C5E1AC6DAAB681EEF1712BD34C2E57 Government of the Walloon Region of Belgium Drs. Henrotin and Gharbi contributed equally to this work. Drs. Henrotin, Gharbi, De Pauw, and Deberg hold patents for biomarkers of osteoarthritis and/or other aging‐related diseases and for the use of these biomarkers (EP 08157521.9, US 121737,051, EP 097557339.8, WO 2009/146956 A1, and 2009/146957.A1). Dr. Henrotin owns stock or stock options in Artialis. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 scopus-id:2-s2.0-84861961870 |
ISSN: | 0004-3591 2326-5191 1529-0131 1529-0131 2326-5205 |
DOI: | 10.1002/art.34392 |